Inmune Bio, Inc. INMB
Bio is a clinical-stage biotechnology company dedicated to developing and commercializing a pipeline of product candidates designed to
reprogram the innate immune system. Our mission is to address a broad range of diseases where chronic inflammation and immune dysfunction
are primary drivers of pathology.
Program: CORDStrom™ for RDEB Our primary focus is the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Last close
1.46
2026-10-23
Market cap
$40.5M
2026-06-30 share count
52-week range
1.09 - 2.60
Valuation FY2025 figures against the last close
P/S810.4x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-1.86
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $50.0K | $14.0K | $155.0K | $374.0K | $181.0K | $11.0K | — | $0 | $0 | — |
| R&D | $20.7M | $33.2M | $20.3M | $17.1M | $20.5M | $5.9M | $3.3M | $3.4M | $435.4K | — |
| SG&A | $10.3M | $9.5M | $9.6M | $9.3M | $8.8M | $6.3M | $6.0M | $9.1M | $546.1K | — |
| Total operating expenses | $47.4M | $42.6M | $29.9M | $26.3M | $29.3M | $12.2M | $7.8M | $12.4M | $981.5K | — |
| Operating income | -$47.4M | -$42.6M | -$29.7M | -$26.0M | -$29.2M | -$12.2M | -$7.8M | -$12.4M | -$981.5K | — |
| Interest expense | — | $789.0K | $2.3M | $2.0M | — | — | — | — | — | — |
| Pre-tax income | $45.9M | $42.1M | $30.0M | — | — | — | — | -$12.4M | -$831.5K | — |
| Income tax | — | — | — | — | — | — | — | $0 | $0 | — |
| Net income | -$46.0M | -$42.0M | -$30.0M | -$27.3M | -$30.3M | -$12.1M | -$7.7M | -$12.4M | -$831.5K | — |
| EPS, basic | -1.86 | -2.11 | -1.67 | -1.52 | -1.88 | — | — | — | — | — |
| EPS, diluted | -1.86 | -2.11 | -1.67 | -1.52 | -1.88 | -1.01 | -0.75 | -1.43 | -0.13 | — |
| Shares, diluted (wtd. avg.) | 24.8M | 19.9M | 18.0M | 17.9M | 16.1M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $24.8M | $20.9M | $35.8M | $52.2M | $74.8M | $22.0M | $7.0M | $186.2K | $1.4M | $141.7K |
| Receivables | $4.3M | $1.2M | $1.9M | — | — | — | — | — | — | — |
| Total current assets | $29.9M | $22.7M | $39.9M | $64.7M | $82.6M | $24.0M | $7.8M | $849.3K | $1.9M | — |
| Property, plant and equipment | $955.0K | — | — | — | — | — | — | — | — | — |
| Other intangibles | — | $16.5M | $16.5M | $16.5M | $16.5M | $16.5M | $16.5M | $16.5M | $16.5M | — |
| Total assets | $32.4M | $39.6M | $57.0M | $81.8M | $99.9M | $40.7M | $24.5M | $17.4M | $18.4M | — |
| Accounts payable | $7.8M | $6.5M | $7.9M | $5.2M | $3.7M | $1.5M | $402.0K | $553.2K | $126.3K | — |
| Short-term debt | — | — | $9.9M | $5.0M | — | — | — | — | — | — |
| Total current liabilities | $8.4M | $7.2M | $18.5M | $10.9M | $4.4M | $1.8M | $700.4K | $823.8K | — | — |
| Long-term debt | — | $15.0M | — | $9.7M | $15.0M | — | — | — | — | — |
| Total liabilities | $8.8M | $7.5M | $18.9M | $21.7M | $19.7M | $1.9M | $860.5K | $823.8K | $309.7K | — |
| Retained earnings | -$209.0M | -$163.1M | -$121.0M | -$91.0M | -$63.7M | -$33.4M | -$21.3M | -$13.6M | -$1.2M | — |
| Total equity | $23.5M | $32.1M | $37.3M | $60.1M | $80.2M | $38.8M | $23.6M | $16.5M | $18.1M | -$149.2K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$22.6M | -$33.4M | -$12.0M | -$22.7M | -$28.5M | -$8.9M | -$5.4M | -$2.1M | -$761.8K | — |
| Depreciation and amortisation | $84.0K | — | — | — | — | — | — | — | — | — |
| Stock-based compensation | $9.9M | $7.6M | $7.4M | $7.1M | $4.8M | $3.1M | $4.1M | $10.0M | $199.6K | — |
| Capital expenditure | $1.0M | — | — | — | — | — | — | — | — | — |
| Investing cash flow | -$1.0M | — | — | — | -$15.0M | — | — | — | -$100.0K | — |
| Financing cash flow | $27.6M | $18.2M | -$4.2M | $729.0K | $96.4M | $23.9M | $12.2M | $900.0K | $2.1M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-047080.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | — | $11.0K | $181.0K | $374.0K | $155.0K | $14.0K | $50.0K |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | — | -$831.5K | -$12.4M | -$7.7M | -$12.1M | -$30.3M | -$27.3M | -$30.0M | -$42.0M | -$46.0M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Other event Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event Item 8.01
- Other event Item 8.01
- Material agreement signed Item 1.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |